Current research on Autism has been making great strides, and a new weapon in the fight against the syndrome is currently under consideration; the possibility that certain proteins derived from jellyfish can possibly alleviate some of the speech problems associated with the condition.
This possible treatment did not come from the usual sources delving into Autism, but rather from researchers focusing on a different syndrome… Amyotrophic Lateral Sclerosis, more commonly known as MND or Lou Gherig’s Disease. One factor of this disease is faulty calcium regulation in the brain, leading to a state of elevated concentrations that damage neurons – and researchers have found that certain jellyfish proteins, specifically apoaequorin, can act as a buffer and reduce the effects of ALS.
One pharmaceutical company attempting to bring such a treatment to market has produced a drug that has shown great promise. Initial research into Prevagen has shown that it can improve memory in subjects, specifically in the areas of learning and word recall, as well as aiding in sleep. Though research into the drug/protein’s impact on ALS can only be called anecdotal at this point it has been reported that, while not halting the progress of the disease, patients who received apoaequorin evidenced progression rates much slower than their counterparts who did not receive the treatment.
At this point there are no studies into the impact of apoaequorin/Prevagen on Autism, but anything that would help protect a patient’s motor neurons from a neurological disease is definitely something to explore!